SH3TC2 and neoplasm: As shown in Figure 3D, in our cohort, we found that higher expression of SH3TC2 in tumor tissue indicated poor DFS of CRC patients (HR = 4.71, 95% CI = 1.85–11.99, p = 0.0038).